Read by QxMD icon Read


shared collection
193 papers 100 to 500 followers
Jessica Liu, Hwai-I Yang, Mei-Hsuan Lee, Richard Batrla-Utermann, Chin-Lan Jen, Sheng-Nan Lu, Li-Yu Wang, San-Lin You, Chuhsing Kate Hsiao, Chien-Jen Chen
UNLABELLED: Spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA undetectability are important milestones of chronic hepatitis B and major treatment endpoints of antiviral therapy. This study investigated the role of serum hepatitis B surface antigen (HBsAg) levels and established models for predicting HBeAg seroclearance and HBV DNA undetectability. A total of 2,139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naïve participants without liver cirrhosis at study entry were included...
July 2014: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
María Reig, Jordi Bruix
No abstract text is available yet for this article.
March 24, 2018: Lancet
Shuntaro Obi, Takahisa Sato, Shinpei Sato, Miho Kanda, Yuta Tokudome, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Toshihiro Kawai, Yuji Kondo, Yoshihiro Isomura, Hiroshi Ohyama, Keiko Nakagomi, Hiroshi Ashizawa, Yuko Miura, Hiroyuki Amano, Hitoshi Mochizuki, Masao Omata
BACKGROUND/PURPOSE: Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1-3, fibroblast GF receptors 1-4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hepatocellular carcinoma. This study examined the efficacy and safety of lenvatinib in a real-world setting. METHODS: This was a retrospective, multicenter, observational study...
January 22, 2019: Hepatology International
Masafumi Ikeda, Masahiro Kobayashi, Makoto Tahara, Shuichi Kaneko
Lenvatinib, a multi-kinase inhibitor, has demonstrated improved outcomes for patients with hepatocellular carcinoma (HCC) in clinical trials. The phase 3 REFLECT trial confirmed the noninferiority of lenvatinib to sorafenib for overall survival of HCC patients and indicated clinical benefits in efficacy over sorafenib. Adverse events (AEs) included hypertension, diarrhea, decreased appetite, decreased weight, fatigue, palmar-plantar erythrodysesthesia, and proteinuria. Areas covered: AEs arising in HCC patients during lenvatinib treatment often lead to treatment interruption, dose reduction, or treatment discontinuation...
November 2018: Expert Opinion on Drug Safety
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem, Jean Frederic Blanc, Arndt Vogel, Dmitry Komov, T R Jeffry Evans, Carlos Lopez, Corina Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann-Lii Cheng
BACKGROUND: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. METHODS: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions...
March 24, 2018: Lancet
A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli
No abstract text is available yet for this article.
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Francesca M Trovato, Liane Rabinowich, Mark J W McPhail
PURPOSE OF REVIEW: This review describes the current intensive care management of acute liver failure (ALF) and the latest evidence for emerging therapies. RECENT FINDINGS: Mortality from ALF continues to improve and in some cases, medical therapy can negate the need for liver transplantation because of protocolized management in specialist centres. Liver transplantation remains the cornerstone of management for poor prognosis ALF. The reduced use of blood products in ALF reflects growing evidence of balanced haemostasis in severe liver disease...
January 28, 2019: Current Opinion in Critical Care
Laurent Castera
Non-alcoholic fatty liver disease is a major cause of liver disease worldwide and the most common liver disorder in Western countries, affecting around 25% of the general population. Fibrosis is the major long-term histological prognostic criteria of this disease. Liver biopsy cannot be realistically performed in such a huge population and, moreover, has well-known limitations (invasiveness, rare but potentially life-threatening complications and sampling variability). Over the past decade, there has been a growing interest in alternative novel strategies for the non-invasive evaluation of fibrosis...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen
Chronic hepatitis B (CHB) infection causes considerable morbidity and mortality and hence should be a target for global elimination. In recent years, advances have been made in understanding the disease pathophysiology and the relationship to clinical outcome. Novel treatment targets are actively being sought in the hope of improving the treatment outlook. Areas covered: We discussed the cascade of cure of CHB with respect to the degree of persistence of viral genome and proteins. Several novel antiviral agents either targeting the virus or the host are in different clinical phases of development...
February 2019: Expert Review of Clinical Pharmacology
Zobair M Younossi
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea. NAFLD and NASH are also associated with a large economic burden and poor health-related quality of life...
November 8, 2018: Journal of Hepatology
Abd Elkhalek Hamed, Medhat Elsahar, Nadia M Elwan, Sarah El-Nakeep, Mervat Naguib, Hanan Hamed Soliman, Ashraf Ahmed Aboubakr, Amany AbdelMaqsod, Heba Sedrak, Samir N Assaad, Reda Elwakil, Gamal Esmat, Samira Salh, Taymour Mostafa, Sherif Mogawer, Sameh Emil Sadek, Maha M Saber, Hanan Ezelarab, Asem Ashraf Mahmoud, Souad Sultan, Mohamed El Kassas, Ehab Kamal, Naglaa M ElSayed, Shorouk Moussa
There is strong association between liver diseases and diabetes (DM) which is higher than expected by a chance association of two very common disorders. It can be classified into three categories: Liver disease related to diabetes, hepatogenous diabetes (HD), and liver disease occurring coincidentally with DM. The criteria for the diagnosis of diabetes associating liver disease are the same for primary diabetes. Two hours post glucose load is a better screening test for HD. HbA1c may not be suitable for diagnosis or monitoring of diabetes associating advanced liver disease...
December 2018: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
Douglas A Simonetto, Laura Piccolo Serafim, Alice Gallo de Moraes, Ognjen Gajic, Patrick S Kamath
Sepsis in patients with cirrhosis is associated with high mortality. An impaired immune response accounts for the increased infection risk observed in these patients. Hemodynamic and systemic changes suggestive of sepsis may be seen in patients with cirrhosis in the absence of infection, therefore diagnosis and treatment of sepsis may be delayed. The optimal management of the critically-ill septic patient with cirrhosis has not been well established and is generally extrapolated from consensus guidelines and expert recommendations made for management of non-cirrhotic patients with sepsis...
December 5, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Sardar Momin Shah-Khan, William Hsueh, Gorman Joel Reynolds
No abstract text is available yet for this article.
January 4, 2019: Gastroenterology
Wai-Kay Seto, Ying-Ru Lo, Jean-Michel Pawlotsky, Man-Fung Yuen
Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality...
November 24, 2018: Lancet
Henry Lik Yuen Chan
Nucleos(t)ide analogs (NAs) are effective, safe, and convenient antiviral therapy to suppress replication of hepatitis B virus, which can be translated into improved long-term outcome of chronic hepatitis B patients. The current recommended first-line NAs, namely, entecavir and tenofovir, are largely free from problems of drug resistance. Nonetheless, there are still a few challenges in the era of NA. First, the risk of hepatocellular carcinoma can only be reduced but not eliminated, particularly among cirrhotic patients...
November 6, 2018: Journal of Gastroenterology and Hepatology
Yuval A Patel, Elizabeth J Gifford, Lisa M Glass, Marsha J Turner, Byungjoo Han, Cynthia A Moylan, Steve Choi, Ayako Suzuki, Dawn Provenzale, Christine M Hunt
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Severe NAFLD with advanced fibrosis results in substantial morbidity and mortality. Associated with metabolic syndrome, NAFLD is often initially clinically silent, yet intensive lifestyle intervention with 7% or greater weight loss can improve or resolve NAFLD. Using a Veterans Health Administration (VHA) liver biopsy cohort, we evaluated simple noninvasive fibrosis scoring systems to identify NAFLD with advanced fibrosis (or severe disease) to assist providers...
September 2018: Digestive Diseases and Sciences
Jean-Luc Raoul, Alejandro Forner, Luigi Bolondi, Tan To Cheung, Roman Kloeckner, Thierry de Baere
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread...
January 2019: Cancer Treatment Reviews
Changjiang Liu, Li Wang, Huizhong Xie, Liyuan Zhang, Bingshu Wang, Chun Luo, Suiqun Wang, Mingliang Tang, Zhongbiao Fu, Hailan Ruan, Zhengjin Liu, Ling Wei, Wenyi Yi, Yunqian Xie
BACKGROUND: There is no consensus regarding the relationship between HBV DNA and liver fibrosis, and the relationship between HBV DNA and the degree of liver cirrhosis has not been reported in patients with chronic HBV infection. METHODS: From January 2011 to December 2016, liver biopsies were performed on 396 patients with chronic hepatitis B and cirrhosis. Assessments of liver fibrosis and cirrhosis were based on the Laennec staging system. RESULTS: Serum levels of HBV DNA were correlated with fibrosis and cirrhosis (KW = 73...
2018: PloS One
Toshihide Shima, Hirofumi Uto, Kohjiro Ueki, Yutaka Kohgo, Kohichiroh Yasui, Naoto Nakamura, Tatsuaki Nakatou, Toshinari Takamura, Sumio Kawata, Kazuo Notsumata, Kyoko Sakai, Ryosuke Tateishi, Takeshi Okanoue
BACKGROUND: We reported a cross-sectional study on causes of liver injury in Japanese type 2 diabetes mellitus (T2D) patients (JG 2013). We assessed overall and cause-specific mortality risk during follow-up of patients enrolled in JG 2013. METHODS: This was a longitudinal, multicenter cohort study. Of the 5642 Japanese T2D patients who visited T2D clinics of nine hospitals in the original study, 3,999 patients were followed up for an average of 4.5 years. Expected deaths in T2D patients were estimated using age-specific mortality rates in the general population (GP) of Japan...
July 13, 2018: Journal of Gastroenterology
Martin C S Wong, Jason L W Huang, Jacob George, Junjie Huang, Colette Leung, Mohammed Eslam, Henry L Y Chan, Siew C Ng
This Review presents current epidemiological trends of the most common liver diseases in Asia-Pacific countries. Hepatitis B virus (HBV) remains the primary cause of cirrhosis; despite declining prevalence in most Asian nations, this virus still poses a severe threat in some territories and regions. Mortality resulting from HBV infection is declining as a result of preventive measures and antiviral treatments. The epidemiological transition of hepatitis C virus (HCV) infection has varied in the region in the past few decades, but the medical burden of infection and the prevalence of its related cancers are increasing...
January 2019: Nature Reviews. Gastroenterology & Hepatology
2018-10-14 01:39:24
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"